Claims for Patent: 6,830,923

Summary for Patent: 6,830,923

Title:	Genetics units for inhibiting the function of RNA
Abstract:	The invention relates to a genetic unit, optionally present as a multiple-copy, for inhibiting RNA. The unit contains the transcription units necessary for transcription by polymerase III and a DNA coding for inhibiting RNA, which is arranged within the unit in such a way that the transcribed RNA is part of the polymerase III transcript. Using these units it is possible to achieve increased stability of the inhibiting RNA, which may occur in the form of ribozymes or antisense-RNAs, whilst maintaining an undiminished activity. The invention further relates to a process for introducing the genetic units into the cell, the use of these units and pharmaceutical preparations containing them.
Inventor(s):	Beug; Hartmut (Vienna, AT), Birnstiel; Max L. (Vienna, AT), Cotten; Matthew (Vienna, AT), Wagner; Ernst (Langenzersdorf, AT), Kandolf; Harald (Vienna, AT)
Assignee:	Boehringer Inglheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	07/947,982
Patent Claims:	1. A polynucleotide molecule, comprising: (a) a first polynucleotide molecule coding for a tRNA; and (b) a second polynucleotide molecule coding for a ribozyme, said second polynucleotide molecule being located between the A- and B-boxes of said first polynucleotide molecule. 2. The polynucleotide molecule of claim 1, wherein said first polynucleotide molecule comprises an ApaI restriction site located between said A and B boxes, and said second polynucleotide molecule is inserted in said ApaI restriction site. 3. The polynucleotide molecule of claim 1, wherein said ribozyme is a hammerhead-type ribozyme. 4. The polynucleotide molecule of claim 1, wherein said first polynucleotide molecule codes for initiation-met tRNA. 5. The polynucleotide molecule of claim 1, wherein said first polynucleotide molecule codes for tyr-tRNA. 6. The polynucleotide molecule of claim 1, further comprising an intron, wherein said intron is part of said second polynucleotide molecule. 7. The polynucleotide molecule of claim 6, wherein said intron is modified by first insertion of a restriction site and a second insertion of nucleotides complimentary to the anticodon triplet, so that the secondary structure of the precursor tRNA is stabilized, while the structures which are critical for splicing are maintained. 8. The polynucleotide molecule of claim 1, wherein said first polynucleotide molecule codes for a tRNA having an anticodon stem and loop region, and wherein said anticodon stem and loop region is longer than the anticodon stem and loop region of the wild-type tRNA. 9. The polynucleotide molecule of claim 8, further comprising a restriction site introduced into the anticodon stem and loop region, and wherein said second polynucleotide molecule is inserted in said restriction site. 10. A polynucleotide molecule, comprising: (a) a first polynucleotide molecule coding for a tRNA; (b) a second polynucleotide molecule coding for a ribozyme, said second polynucleotide molecule being located between the A- and B-boxes of said first polynucleotide molecule; and (c) an intron that is part of said second polynucleotide molecule. 11. The polynucleotide molecule of claim 10, wherein said intron is modified by a first insertion of a restriction site and a second insertion of nucleotide complimentary to the anticodon triplet, so that the secondary structure of the precursor tRNA is stabilized, while the structures which are critical for splicing are maintained. 12. A polynucleotide molecule, comprising: (a) a first polynucleotide molecule coding for a tRNA having an anticodon stem and loop region, wherein said anticodon stem and loop region is longer than the anticodon stem and loop region of the wild-type tRNA; and (b) a second polynucleotide molecule coding for a ribozyme, said second polynucleotide molecule being located between the A- and B-boxes of said first polynucleotide molecule. 13. A polynucleotide molecule, comprising: (a) a first polynucleotide molecule that is transcribed by RNA polymerase III; and (b) a second polynucleotide molecule coding for an RNA-inhibiting RNA located within said first polynucleotide molecule, wherein said RNA-inhibiting RNA is not an antisense molecule. 14. The polynucleotide molecule of claim 13, wherein said first polynucleotide molecule codes for a tRNA. 15. The polynucleotide molecule of claim 14, wherein said first polynucleotide molecule codes for initiation-met tRNA. 16. The polynucleotide molecule of claim 14, wherein said first polynucleotide molecule codes for tyr-tRNA. 17. The polynucleotide molecule of claim 14, further comprising an intron, wherein said intron is part of said second polynucleotide molecule. 18. The polynucleotide molecule of claim 14, wherein said first polynucleotide molecule codes for a tRNA having an anticodon stem and loop region, and wherein said anticodon stem and loop region is longer than the anticodon stem and loop region of the wild-type tRNA. 19. The polynucleotide molecule of claim 18, further comprising a restriction site introduced into the anticodon stem and loop region, and wherein said second polynucleotide molecule is inserted in said restriction site. 20. A nucleic acid molecule, comprising: (a) a first polynucleotide molecule that is transcribed by RNA polymerase III; and (b) a second polynucleotide molecule coding for an RNA-inhibiting RNA that is not an antisense molecule, wherein said second polynucleotide molecule is inserted within said first polynucleotide molecule in such a way that, when said nucleic acid molecule is transcribed by RNA polymerase III, the transcription rate of said nucleic acid molecule and the stability of the resulting transcript are maintained. 21. The nucleic acid molecule of claim 20, wherein said RNA-inhibiting RNA is a ribozyme. 22. The nucleic acid molecule of claim 20, wherein said first polynucleotide molecule codes for a tRNA. 23. The nucleic acid molecule of claim 20, wherein said first polynucleotide molecule codes for initiation-met tRNA. 24. The nucleic acid molecule of claim 20, wherein said first polynucleotide molecule codes for tyr-tRNA. 25. The nucleic acid molecule of claim 20, further comprising an intron, wherein said intron is part of said second polynucleotide molecule. 26. The nucleic acid molecule of claim 20, wherein said first polynucleotide molecule codes for a tRNA having an anticodon stem and loop region, and wherein said anticodon stem and loop region is longer than the anticodon stem and loop region of the wild-type tRNA. 27. The nucleic acid molecule of claim 26, further comprising a restriction site introduced into the anticodon stem and loop region, and wherein said second polynucleotide molecule is inserted in said restriction site.

Details for Patent 6,830,923

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-12-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-12-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-12-14